U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07174375) titled 'PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy' on Sept. 12.
Brief Summary: This is a prospective, multicenter, randomized controlled clinical study to evaluate the efficacy of PCSK9 inhibitor in addition to standard therapy in patients with acute ischemic stroke undergoing endovascular therapy.
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Acute Ischemic Stroke
Intervention:
DRUG: PCSK9 inhibitor
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors are a class of monoclonal antibody drugs that lower low-density lipoprotein cholesterol (LDL-C) by inhibiting t...